Allergopharma GmbH & Co. KG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Subsidiary
- Established
- 1969-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.allergopharma.de
Clinical Trials
46
Active:22
Completed:21
Trial Phases
4 Phases
Phase 1:20
Phase 2:6
Phase 3:14
+1 more phases
Drug Approvals
3
NMPA:3
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)• Click on a phase to view related trials
Phase 1
20 (47.6%)Phase 3
14 (33.3%)Phase 2
6 (14.3%)Phase 4
2 (4.8%)Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
Not yet recruiting
- Conditions
- Allergic Rhinitis Due to House Dust MiteAllergic Conjunctivitis Due to Dermatophagoides FarinaeAllergic Conjunctivitis Due to Dermatophagoides PteronyssinusAllergic Asthma Due to Dermatophagoides FarinaeAllergic Asthma Due to Dermatophagoides Pteronyssinus
- First Posted Date
- 2025-07-31
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 105
- Registration Number
- NCT07096440
Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials
Phase 2
Terminated
- Conditions
- Allergic RhinoconjunctivitisHealthy Volunteers
- Interventions
- Drug: PlaceboBiological: Allergovit 6-grasses
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 158
- Registration Number
- NCT02297490
- Locations
- 🇨🇦
Inflamax Research INC, Mississauga, Ontario, Canada
Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis
Phase 2
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- Interventions
- Drug: PlaceboBiological: rBet v1-FV
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 37
- Registration Number
- NCT01490411
- Locations
- 🇩🇪
Allergopharma GmbH & Co. KG, Hamburg, Reinbek, Germany
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
Phase 3
Completed
- Conditions
- RhinoconjunctivitisAllergic Asthma
- Interventions
- Drug: Grass pollen specific immunotherapyDrug: Placabo
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 195
- Registration Number
- NCT01353755
- Locations
- 🇩🇪
Allergopharma GmbH & Co. KG, Hamburg, Reinbek, Germany
Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative
Phase 2
Completed
- Conditions
- Allergic Rhinoconjunctivitis
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Allergopharma GmbH & Co. KG
- Target Recruit Count
- 14
- Registration Number
- NCT00841516
- Locations
- 🇸🇪
Prof. Dr. med. Sabina Rak, Gothenburg, Sweden
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found